With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on the shares. The Q4 ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236.Discover the Best Stocks and ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether ...

Investors have grown concerned about the sector amid reports — which became reality — that President Trump would tap Robert F ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...